Recently, an agonistic antibody targeting TREM2 (AL002; INVOKE-2 trial) was evaluated in patients with Alzheimer’s disease to test the therapeutic potential of modulating microglial function through the TREM2 pathway. Here, TREM2 is linked to Alzheimer disease.